Chromium

The VerdictMODERATE CONVICTIONWorth-It: Low ROI (45/100)

Chromium works for poorly-controlled type 2 diabetics on a chromium-depleted diet.

If you do not have type 2 diabetes with poor blood-sugar control, the chromium capsule in your cabinet is not doing anything. The headline meta-analysis benefit lives in a narrow disease subgroup. Healthy adults, dieters, and "metabolic optimizers" — save your money and eat whole grains, broccoli, lean meat, brewer's yeast, and nuts.

HbA1c reduction in T2D (chromium-depleted / non-Western): MODERATE. Foroutan 2014 PMID:24635480 MA (HbA1c −0.55%); Suksomboon 2014 PMID:25971249 MA N=875; Anderson 1997 PMID:9356027 Chinese T2D N=180.
HbA1c reduction in T2D (Western insulin-treated, replete): DEBUNKED. Kleefstra 2006 PMID:16505499 N=46 null at 500 + 1000 µg/d. Kleefstra 2007 PMID:17303791 chromium yeast null.
Insulin sensitivity (clamp-measured) in T2D: MODERATE. Martin 2006 PMID:16873787 N=29 industry-funded clamp.

That's the general answer. Your stack is different.

Check your whole stack

The Protocol

Population	Dose	Timing	Form	Source
Healthy adults (general)	No capsule	n/a	Food: whole grains, broccoli, lean meat, brewer's yeast, nuts	EFSA 2014 / IOM 2001 [cite-unverified]
T2DM with HbA1c ≥7% (chromium-depleted likely)	200–1000 µg/d	With meals (carbohydrate co-ingestion improves absorption)	Chromium picolinate (CrPic)	Foroutan 2014 PMID:24635480 MA; Suksomboon 2014 PMID:25971249 MA; Anderson 1997 PMID:9356027
T2DM Western insulin-treated, obese	Not justified	n/a	n/a	Kleefstra 2006 PMID:16505499 null at 500 + 1000 µg/d
Non-diabetic adult with metabolic syndrome	Not justified	n/a	n/a	Iqbal 2009 PMID:19422140 clean null at 1000 µg/d
Overweight adult seeking weight loss	Not justified	n/a	n/a	Onakpoya 2013 [cite-unverified] −0.5 kg below clinical relevance
PCOS women (alongside primary care)	200–1000 µg/d × 8–24 wk	With meals	Chromium picolinate	2025 PCOS MA PMID:41067797 (N=683, direction-only)

Forms Comparison

Chromium picolinate (CrPic)

~1.2–2.8% absorbed · £4–10/mo

The form with the meta-analysis-level evidence in T2D. The default. Used in Foroutan 2014, Suksomboon 2014, Anderson 1997.

Chromium polynicotinate

No human head-to-head PK · £10–25/mo

Marketed as "niacin-bound, superior absorption" with no human PK trial or head-to-head outcome RCT to support it. Premium with no documented advantage.

Chromium yeast (food-form)

No head-to-head · £8–15/mo

Kleefstra 2007 tested chromium yeast at 400 µg/d in Western T2D on oral hypoglycemics and found NULL effect on glycemic control. Whole-food matrix but not equivalent to CrPic in evidence base.

Chromium dinicocysteinate (CDNC)

No human PK · £15–30/mo

Jain 2012 N=100 T2D showed within-arm signals on insulin, TNF-α, oxidative stress. Never independently replicated. 3–5× CrPic price with single-trial evidence base.

"GTF chromium"

Defunct chemical concept · £15–40/mo

"Glucose Tolerance Factor" was a 1950s biochemical hypothesis replaced by the chromodulin (LMWCr) model in current biochemistry. Selling "GTF chromium" supplements in 2026 is selling a chemical concept that does not exist as a defined entity.

Hexavalent chromium Cr(VI)

NEVER FOR HUMAN USE

Industrial and environmental form (electroplating, groundwater contamination). IARC Group 1 human carcinogen. Different biology from supplement-form Cr(III). Public confusion of the two valences is common.

Absorption note: Chromium absorption is genuinely poor (1–3% across forms). Co-ingestion with vitamin C and carbohydrate increases absorption. Calcium carbonate antacids, PPIs, and H2 blockers reduce it. Separate from levothyroxine doses by ≥4 hours.

Safety & Interactions

Regulatory anchors: EFSA 2014 [cite-unverified] reclassified Cr(III) as NON-essential and identified a tolerable supplemental intake of 250 µg/d Cr(III). IOM 2001 [cite-unverified] kept an Adequate Intake of 25 µg/d (women 19–50) / 35 µg/d (men 19–50) but never set an RDA or UL. Practical operating ceiling for consumer use is 1000 µg/d CrPic — the upper dose used in MA-positive trials and the threshold above which case-report renal/hepatic signals dominate.

Levothyroxine (moderate)

Chromium binds levothyroxine in the GI tract, reducing absorption. Separate doses by ≥4 hours.

Insulin, sulfonylureas, metformin (moderate)

Additive hypoglycemia risk in chromium-responder T2D phenotype. Monitor blood glucose when adding chromium to antidiabetic therapy; the prescribing clinician may adjust the antidiabetic dose.

Antacids (calcium carbonate), H2 blockers, PPIs (mild)

Reduce gastric acid and chromium absorption. Take chromium with a meal; separate from antacids.

NSAIDs — aspirin, ibuprofen (theoretical)

May increase chromium absorption and retention. No documented clinical event; no specific action required.

Contraindicated populations

Pregnancy / lactation — Supplementation above the AI is not supported by safety data. Diet covers the AI.
CKD stage 3+ — Chromium is renally excreted; supplementation may accumulate (Wani 2011 [cite-unverified] case-series on chronic high-dose CrPic renal toxicity).
Active hepatic disease — Cerulli 1998 [cite-unverified] reported case-level CrPic hepatotoxicity at chronic high doses.
Type 1 diabetes — Insulin-dependent; chromium has not been tested for safety on insulin requirements in T1D and may increase hypoglycemia risk.
Children — No efficacy evidence; narrower safety margins. Use food sources only.

Side effects

GI upset, nausea, headache (uncommon at ≤1000 µg/d) — take with food, reduce dose if persists
Hypoglycemia when co-administered with insulin/sulfonylurea in responder T2D (rare) — clinician dose adjustment
Acute interstitial nephritis / acute tubular necrosis (rare case-reports at chronic 1200–2400 µg/d CrPic, Wani 2011 [cite-unverified]) — stop, evaluate renal function
Hepatitis / liver enzyme elevation (rare case-reports at chronic high-dose, Cerulli 1998 [cite-unverified]) — stop, evaluate LFTs

Cr(III) is not Cr(VI). Supplement chromium is trivalent Cr(III) — the supplement form with the safety profile above. Hexavalent Cr(VI) is the industrial / environmental form (electroplating, groundwater) and is an IARC Group 1 human carcinogen. Public confusion of the two valences is common; supplement Cr(III) at consumer doses is not the carcinogenic Cr(VI).

Conviction: MODERATE (endpoint-stratified)

The MA-level evidence (Foroutan 2014, Suksomboon 2014) supports MODERATE conviction for chromium picolinate in T2DM HbA1c / FPG reduction in chromium-depleted or non-Western populations. The same evidence base reads DEBUNKED in Western insulin-treated T2D (Kleefstra 2006), DEBUNKED for metabolic syndrome in non-diabetic adults (Iqbal 2009), and DEBUNKED for clinically meaningful weight loss in overweight adults (Onakpoya 2013 [cite-unverified]). Per-endpoint conviction is detailed below.

What would change this

A pre-registered, independent (non-industry-funded), placebo-controlled RCT of ≥300 chromium-replete Western adults with metabolic syndrome (no T2D), on CrPic 400–1000 µg/d for 24 weeks, with clamp-measured insulin sensitivity AND HbA1c as primary endpoints AND documented baseline serum/urinary chromium status, showing a between-group HbA1c reduction of ≥0.3% absolute, would upgrade healthy-MetS adults from DEBUNKED to MODERATE.
A ≥500-subject 52-week RCT at 1000 µg/d showing ≥3% body-weight loss vs placebo at clinical relevance threshold would resolve the weight-loss claim. Onakpoya 2013's −0.5 kg signal has had 12 years to be replicated at meaningful magnitude and has not been.
A head-to-head human PK study (n≥30) of polynicotinate or dinicocysteinate vs CrPic AND a head-to-head outcome RCT at matched elemental dose showing the premium form delivers ≥30% greater HbA1c effect would settle the premium-form question.
A pre-registered N≥200 independent (non-industry-funded) replication of Albarracin's CrPic + biotin combo trials would clarify whether the combo signal is chromium, biotin, or both.

Worth Your Money?

Estimated weekly cost

£1–£2.50 for chromium picolinate at 200–1000 µg/d. £2.50–£10 for premium polynicotinate / dinicocysteinate / "GTF chromium" with no human PK or outcome RCT supporting the markup.

Worth it if

You have type 2 diabetes with HbA1c ≥7% on stable antidiabetic therapy, and your prescribing clinician agrees a 12–24 week trial of chromium picolinate at 200–1000 µg/d is reasonable as an adjunct. Reassess at 12 weeks. Discontinue if HbA1c hasn't moved 0.3% absolute.

Lower priority if

Your sleep is short, your training is inconsistent, your protein intake is low, or you have not yet corrected a documented vitamin D deficiency. Those dollars deliver more than a chromium capsule will. For pre-T2D and metabolic risk, weight loss + resistance training + walking volume are the first-dollar levers; chromium sits well below them.

Conditional · Skip for Healthy Adults

Sources

Vajdi M et al. (2024) J Trace Elem Med Biol PMID:37952433. Dose-response SR/MA on chromium and body composition in T2D.
Suksomboon N et al. (2014) Nutr J PMID:25971249. MA of chromium on HbA1c and FPG in diabetes, N=875.
Foroutan F et al. (2014) J Clin Pharm Ther PMID:24635480. MA of chromium efficacy and safety in diabetes — HbA1c −0.55%, FPG reduced, TG lowered, HDL increased.
2025 PCOS chromium SR/MA, Endocrinol Diabetes Nutr PMID:41067797. MA across 10 RCTs N=683 women with PCOS.
Anderson RA et al. (1997) Diabetes PMID:9356027. RCT N=180 Chinese T2D, 200 vs 1000 µg/d CrPic, 4 months. Landmark positive trial.
Kleefstra N et al. (2006) Diabetes Care PMID:16505499. DB RCT N=46 obese insulin-treated Western T2D, CrPic 500 + 1000 µg/d, 6 months. NULL.
Kleefstra N et al. (2007) Diabetes Care PMID:17303791. DB RCT Western T2D, chromium yeast 400 µg/d, 6 months. NULL.
Albarracin CA et al. (2008) Diabetes Metab Res Rev PMID:17506119. DB RCT N=447 poorly-controlled T2D, CrPic + biotin, 90 days. Industry-funded (Nutrition 21).
Iqbal N et al. (2009) Metab Syndr Relat Disord PMID:19422140. DB RCT N=63 obese non-diabetic MetS, CrPic 1000 µg/d, 16 weeks. CLEAN NULL.
Martin J et al. (2006) Diabetes Care PMID:16873787. DB RCT N=29 T2D on sulfonylurea, CrPic 1000 µg/d + glipizide, 24 weeks. Industry-funded clamp.
Paiva AN et al. (2015) J Trace Elem Med Biol PMID:26302914. RCT N=71 T2D, CrPic 600 µg/d, 4 months. HbA1c reduction in CrPic arm.
Jain SK et al. (2012) Mol Nutr Food Res PMID:22674882. DB RCT N=100 T2D, chromium dinicocysteinate vs CrPic vs placebo.
Docherty JP et al. (2005) J Psychiatr Pract PMID:16184071. CrPic in atypical depression pilot, N=41. Industry-funded.
Krikorian R et al. (2010) Nutr Neurosci PMID:20423560. Chromium and cognitive-cerebral function in older adults, N=26.
Anton SD et al. (2008) Diabetes Technol Ther PMID:18715218. CrPic on food intake and satiety, N=42.
Vrtovec M et al. (2005) Am Heart J PMID:15990745. CrPic and QTc interval in T2D, N=60.
Albarracin C et al. (2007) J Cardiometab Syndr PMID:17684468. CrPic + biotin and coronary risk factors, N=348. Industry-funded.
Onakpoya I, Posadzki P, Ernst E (2013) Obes Rev [cite-unverified]. SR/MA of chromium for overweight/obesity — −0.50 kg vs placebo.
Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG (2007) Diabetes Care [cite-unverified]. Landmark counterweight SR of 41 RCTs.
EFSA Panel on Food Additives (2014) EFSA Journal [cite-unverified]. Reclassified Cr(III) as non-essential; tolerable supplemental intake 250 µg/d.
Institute of Medicine (2001) DRIs for trace minerals [cite-unverified]. AI 25–35 µg/d for adults; no RDA, no UL.
NIH Office of Dietary Supplements (2022) Chromium Fact Sheet [cite-unverified]. Drug interactions, form comparisons, case-report toxicity.
Mobarhan MG, Aliasghari F (2020) Clin Nutr Res [cite-unverified]. RCT N=52 T2D, CrPic 400 µg/d, 8 weeks. Null between-group; within-arm HOMA-IR only.

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score

45/100 Low ROI Trust grade C

No for almost everyone. The appetite and weight story is a clean null, and the blood-sugar effect is real only for a narrow diabetic subgroup.

Time

Low

Money

Low

Effort

Low

Risk

Low

Why this score

The appetite and weight-loss half, which is why most people buy it, is a clean null. The weight-loss meta found just -0.50 kg over 8 to 24 weeks (Onakpoya 2013), which is about half a percent of body weight, well under the 3 to 5 percent clinicians call meaningful.
The blood-sugar half works only in a narrow group. HbA1c fell 0.55 percent in diabetics who were likely chromium-depleted (Foroutan 2014; Anderson 1997, N=180 Chinese T2D), but it was a clean null in Western insulin-treated diabetics (Kleefstra 2006, N=46) and in non-diabetic metabolic-syndrome adults (Iqbal 2009, N=63). For a healthy buyer there is nothing to fix.
Trust is C-grade and I am highly confident the signal is subgroup-only: the positive numbers come from older, non-Western, or lower-quality trials, and the largest 'positive' trials used a chromium-plus-biotin combo funded by the patent holder.
Cost is genuinely low, about $4 to $10 a month for chromium picolinate, but premium forms (polynicotinate, dinicocysteinate, 'GTF') charge 2 to 5 times more for no proven advantage. Cheap is the only thing this has going for it.
Risk is low, with occasional GI upset and a hypoglycemia caution only when stacked on diabetes drugs, plus rare kidney and liver case reports above 1,000 mcg/day. Low risk does not rescue a near-zero benefit for the average buyer.

Why it didn’t score higher

The two things most buyers want, appetite control and fat loss, are not supported. Half a kilo over six months is statistical noise dressed as a result.
The blood-sugar benefit does not generalize to the people the marketing implies, and a Western diet already meets the small chromium requirement.
Premium forms are a straightforward trap, charging more for absorption claims that no human head-to-head trial supports.

Best for

Type 2 diabetics with poor glycemic control (HbA1c at or above 7 percent) and a plausibly chromium-depleted diet, trialing it under a prescribing clinician
PCOS patients trialing it alongside primary care for metabolic and androgen parameters (direction-only evidence)
Non-Western or older diabetics in low-chromium dietary patterns (the original positive-signal group)

Lower ROI if

You are a healthy adult with no metabolic disease (nothing to rescue in a replete system)
Your goal is appetite control or weight loss (the evidence is a clinically meaningless -0.5 kg)
You are a Western insulin-treated diabetic or have non-diabetic metabolic syndrome (clean nulls)
You pay a premium for polynicotinate, dinicocysteinate, or 'GTF' chromium (no proven superiority)
You have CKD stage 3 or higher, active liver disease, type 1 diabetes, or are pregnant

Minimum effective dose

For the only supported use, type 2 diabetes with poor control: 200 to 1,000 mcg/day of chromium picolinate with a carbohydrate-containing meal, for 12 to 24 weeks, under a clinician, then reassess HbA1c (Foroutan 2014; Anderson 1997). For appetite, weight loss, or healthy adults, the minimum effective dose is zero because there is no benefit.

Track this

If trialing for diabetes: HbA1c at 12 to 24 weeks, and stop if the absolute drop is under 0.3 percent
Blood glucose, especially if also on insulin or a sulfonylurea
Honestly, for appetite or weight there is nothing meaningful to track because there is no effect